Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study.
Pallarés-Carratalá V, Ruiz-García A, Serrano-Cumplido A, Fragoso AS, Fernández-Pascual V, Sánchez-Sánchez B, Cervera-Pérez MI, Alonso-Moreno FJ, Arranz-Martínez E, Barquilla-García A, Rey-Aldana D, García JP, Cinza-Sanjurjo S; Investigators of the AGORA study, of the Spanish Society of Primary Care Physicians SEMERGEN Foundation.
Pallarés-Carratalá V, et al. Among authors: arranz martinez e.
Clin Investig Arterioscler. 2024 Jun 22:S0214-9168(24)00043-3. doi: 10.1016/j.arteri.2024.05.001. Online ahead of print.
Clin Investig Arterioscler. 2024.
PMID: 38910079
English, Spanish.